DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Citalopram for Cocaine Dependence

Information source: The University of Texas Health Science Center, Houston
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cocaine Dependence

Intervention: Citalopram (Drug); Citalopram (Drug); Placebo (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Joy Schmitz

Official(s) and/or principal investigator(s):
Joy M Schmitz, Ph.D., Principal Investigator, Affiliation: University of Texas at Houston

Overall contact:
Jessica Vincent, BS, Phone: 7135003784, Email: Jessica.Vincent@uth.tmc.edu


This is a phase 2 clinical trial of citalopram pharmacotherapy for treatment of cocaine dependence. Using a double-blind, randomized controlled design, eligible cocaine dependent patients will be assigned equally to one of three medication conditions: placebo or the Selective serotonin re-uptake inhibitor (SSRI) agent, citalopram at either 20 mg per day or 40 mg per day. It is hypothesized that citalopram will reduce cocaine use and increase periods of sustained abstinence substantially more than placebo. Performance on a set of behavioral tasks of impulsivity will be analyzed as potential predictors of treatment response.

Clinical Details

Official title: Clinical Trial of Serotonin Medication Combination in Cocaine Dependence

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Abstinence

Secondary outcome:

Cocaine Use Days

Cocaine-negative Urines

Retention in Treatment


Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.


Inclusion Criteria:

- between 18 and 60 years of age

- meet DSM-IV criteria for current cocaine dependence

- be in acceptable health on the basis of interview, medical history and physical exam

- able to provide the names of at least 2 persons who can generally locate their

whereabouts. Exclusion Criteria:

- diagnosis of any psychoactive substance dependence other than cocaine, marijuana, or


- have a psychiatric disorder or neurological disease or disorder requiring ongoing

treatment and/or making study participation unsafe

- medical conditions contraindicating citalopram pharmacotherapy

- taking medications known to have significant drug interactions with the study


- pregnant or nursing for female patients

- having plans to leave the immediate geographical area within 3 months

Locations and Contacts

Jessica Vincent, BS, Phone: 7135003784, Email: Jessica.Vincent@uth.tmc.edu

UT-Houston Behavioral and Biomedical Sciences Building, Houston, Texas 77054, United States; Recruiting
Jessica Vincent, BS, Phone: 713-500-3784, Email: Jessica.Vincent@uth.tmc.edu
Joy M Schmitz, Ph.D., Principal Investigator
Additional Information

Starting date: December 2010
Last updated: February 14, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017